文献速递头颈部肿瘤放疗姑息放疗与转移瘤

头颈癌放疗患者经济毒性与治疗结局的关联

Financial toxicity on treatment outcomes in head & neck cancer patients undergoing radiation therapy.
PubMed 文献 · Radiat Oncol · 2025-11-25

该前瞻性研究纳入74例接受放疗的头颈癌患者,采用FACIT-COST量表评估经济毒性,发现放疗前COST评分较低者具有更差的生活质量、更重的症状负担及更多计划外医疗使用,且放疗前后较低COST评分均与更差的总生存显著相关。

要点

  • 头颈癌放疗患者经济毒性常见,41.9%放疗前COST评分≤25。
  • 经济毒性较重者更年轻、黑人、医疗补助保险、单身或失业、T分期晚及同步放化疗。
  • 放疗前后较低COST评分均与更差总生存独立相关。

核心结论

  • 经济毒性在头颈癌放疗患者中普遍存在,并与较差的生活质量、治疗相关疾病负担及总生存相关。

研究设计与样本

  • 前瞻性研究,连续纳入2021年7月至2023年6月转诊至三级中心接受放疗的头颈癌患者,共74例,中位年龄69岁。

主要发现

  • 74例患者均完成放疗前评估,39例完成放疗后评估;放疗前COST中位评分为29(范围0-44),41.9%评分≤25。
  • 放疗前COST评分较低与更年轻、黑人种族、医疗补助保险、单身或失业、较晚T分期及同步放化疗相关(p<0.05)。
  • 放疗前COST评分较低者生活质量更差、症状更重、胃管置入更多、急诊就诊/住院更多(p<0.05)。
  • 放疗前COST评分较低与更差总生存相关(HR=0.95;95%CI=0.91-0.99;p=0.015),放疗后COST评分较低亦与更差总生存相关(HR=0.92;95%CI=0.86-0.98;p=0.012)。

关键数值与推荐

  • 经济毒性采用FACIT-COST量表评估,评分越低表示经济毒性越重。
  • 生活质量采用EORTC-QLQ-C30评估,症状负担采用PRO-CTCAE评估。
  • 主要结局包括两年总生存、治疗相关疾病负担(急诊就诊、住院、胃管置入、放疗中断天数)、生活质量及症状负担。

临床怎么用

  • 对头颈癌放疗患者应在放疗前常规筛查经济毒性,尤其关注年轻、黑人、医疗补助保险、单身或失业及接受同步放化疗者。
  • 对经济毒性较重者需加强支持治疗,关注胃管置入、急诊就诊及住院风险,并评估生活质量与症状负担。

局限性

  • 样本量较小(74例),仅39例完成放疗后评估,可能存在选择偏倚。
  • 单中心三级转诊研究,结果外推需谨慎。
  • 为观察性研究,无法确定经济毒性与不良结局的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Financial toxicity, defined as hardship from medical costs, is an emerging concept in healthcare. Here we define financial toxicity in head and neck cancer patients receiving radiation, identify risk factors, and determine associations with HRQoL, treatment morbidity, and survival. METHODS: We conducted a prospective study on consecutive patients referred to a tertiary referral center for radiation therapy for head and neck malignancies (July 2021-June 2023). Patients provided consent and were assessed using validated patient-reported outcome measures for financial toxicity (FACIT-COST), HRQoL (EORTC-QLQ-C30), and symptom burden (PRO-CTCAE) before and after radiation therapy. Primary outcomes included two-year overall survival (OS), treatment morbidity (ER visits, hospitalizations, feeding tube placement, missed radiation days), HRQoL, and symptom burden. RESULTS: Among 74 patients (median age 69), all completed pre-radiation therapy (pre-RT) measures, and 39 completed post-RT measures. Median pre-RT COST was 29 (range: 0-44), with 41.9% scoring ≤25, indicating worse financial toxicity. Lower pre-RT COST scores correlated with younger age, Black race, Medicaid insurance, single or unemployed status, advanced T-stage, and concurrent chemoradiotherapy (p < 0.05). These patients had worse HRQoL, more severe symptoms, increased feeding tube placements, and more ER visits/hospitalizations (p < 0.05). OS was worse with lower pre- (HR = 0.95; 95% CI = 0.91-0.99; p = 0.015) and post-RT COST scores (HR = 0.92; 95% CI = 0.86-0.98; p = 0.012). CONCLUSIONS: Financial toxicity is common in head and neck radiation patients and linked to worse HRQoL, morbidity, and OS. Affected patients had clear socioeconomic risk factors and advanced disease. Further research should explore interventions to improve cancer outcomes.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Harada GK, Ku E, Park J, et al. Financial toxicity on treatment outcomes in head & neck cancer patients undergoing radiation therapy. Radiat Oncol. 2025. PMID: 41291797. doi:10.1186/s13014-025-02749-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。